Cancer Treatment Centers of America at Midwestern Regional Medical Center to Participate in AccuBoost Accelerated Dose Clinical Trial

CHICAGO, April 1, 2015 /PRNewswire/ -- Patients who undergo breast conservation therapy have an even stronger defense to prevent disease recurrence and rid the body of cancer cells following a lumpectomy with the use of AccuBoost®. Cancer Treatment Centers of America® (CTCA) at Midwestern Regional Medical Center (Midwestern) has been invited by Rhode Island Hospital to participate in a new clinical trial, BR-291, pairing noninvasive image-guided brachytherapy (NIBB) with accelerated partial breast irradiation (APBI) in a five-fraction dose. CTCA® will follow trial guidelines by utilizing AccuBoost technology to provide precise radiation treatment targeting the tumor bed while reducing radiation exposure to healthy tissue as part of their integrative breast cancer treatment program in as little as a five-day treatment program.

AccuBoost is delivered using real-time imagery, where radiation oncologists pinpoint the tissue that needs to be treated, and deliver a dose of radiation to the lumpectomy site. Radiation is delivered both vertically and horizontally, overlapping the lumpectomy site to irradiate cancer cells in the breast tissue known to be the most likely site of disease recurrence if left untreated. AccuBoost has minimal discomfort and delivers a targeted beam of radiation to the surgical excision site. During the procedure, the breast is immobilized by compressing it slightly.

"The practice of performing a lumpectomy followed by radiation has been successfully used for years to help women overcome cancer and prevent disease recurrence," said Sung Chang, MD, radiation oncologist and primary investigator for the trial at CTCA at Midwestern. "Participation in the AccuBoost accelerated dose clinical trial provides patients battling breast cancer with even more access to treatment options."

For more information about breast cancer treatments available at CTCA at Midwestern, visit http://www.cancercenter.com/midwestern/medical-departments/breast-center-of-excellence/

To learn more about the clinical trial and participation requirements, visit clinicaltrials.gov/ct2/show/NCT01961531.

About AccuBoost®
AccuBoost is the mammography-guided non-invasive brachytherapy procedure for patients with early stage breast cancer.  The procedure may be employed as a boost to the tumor bed or as a monotherapy option for Accelerated Partial Breast Irradiation (APBI). For more information on AccuBoost, and how typical treatments utilizing the AccuBoost Applicators are delivered, visit AccuBoost's recently updated website http://www.accuboost.com or email [email protected].

About Cancer Treatment Centers of America®
Cancer Treatment Centers of America, Inc. (CTCA) is a national network of five hospitals that specialize in the treatment of patients fighting complex or advanced-stage cancer. CTCA offers an integrative approach to cancer treatment that combines surgery, radiation, and chemotherapy with nutritional counseling, naturopathic medicine, mind-body therapy, and spiritual support to enhance quality of life and minimize side effects during treatment. The company serves patients from all 50 states at hospitals located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Standard^® of care and Patient Empowerment Medicine^®, CTCA provides patients with comprehensive information about their treatment options so they can participate in their treatment decisions. For more information about CTCA, go to www.cancercenter.com.

About Cancer Treatment Centers of America at Midwestern Regional Medical Center
Cancer Treatment Centers of America^® (CTCA) at Midwestern Regional Medical Center is a 73 bed specialty hospital dedicated to treating patients battling complex cancer. CTCA^® at Midwestern is nationally recognized for providing innovative and individualized cancer care and has been designated by the American Nurses Credentialing Center (ANCC) a Magnet Recognized® program, ranking the hospital as one of the top seven percent in the nation for nursing excellence. CTCA at Midwestern has been designated by the National Quality Measures for Breast Centers Program (NQMBC^®) as a Certified Quality Breast Center of Excellence™, ranking the hospital among the top centers in the country for quality breast cancer care. CTCA at Midwestern is the only Certified Breast Center of Excellence in Illinois, and one of only 41 nationally. As a member of the National Marrow Donor Program (NMDP) the hospital also offers a Stem Cell Transplant and Cell Therapy program that provides a full spectrum of transplantation services and advanced treatment options for hematologic cancers. CTCA is recognized by the Foundation for the Accreditation of Cellular Therapy (FACT) at the University of Nebraska Medical Center for demonstrating compliance with the FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing and Administration. CTCA at Midwestern is also recognized by the Quality Oncology Practice Initiative (QOPI®) Certification Program, an affiliate of the American Society of Clinical Oncology (ASCO), for meeting the highest standards for quality cancer care. CTCA at Midwestern is proud to use the latest technology to offer advanced treatment for cancer and is currently one of only a few hospitals in the nation to combine recent advances in brain mapping and navigation to perform minimally invasive brain surgery on hard to reach brain tumors.

 Logo - http://photos.prnewswire.com/prnh/20090612/CTCALOGO

SOURCE Cancer Treatment Centers of America, Inc.

Related Links

http://www.cancercenter.com